Formulation Development and Evaluation of Dextran Nanoparticles Enclosed with Recombinant Typhoid (Ty21a) Antigen

Abstract

Developing efficacious vaccines for Typhoid fever continues to be a paramount concern in global health, particularly in areas with a significant prevalence of the illness. This research focused on the synthesis, refinement, and analysis of recombinant Typhoid (Ty21a) antigen-encapsulated Eudragit-coated dextran nanoparticles. These nanoparticles function as an innovative platform for delivering the Ty21a antigen, which has the potential to enhance vaccination durability and effectiveness. The synthesis process was methodically adjusted to get optimal nanoparticle size, shape, and surface qualities by manipulating several formulation factors. The physicochemical evaluation verified the generation of precisely specified nanoparticles that effectively encapsulate the Ty21a antigen. The in vitro release assays shown that the Eudragit-coated nanoparticles can release antigens in a sustained and regulated manner, suggesting that they have the ability to provide prolonged immune activation. This study demonstrates the potential of using recombinant Typhoid antigen-encapsulated Eudragit-coated dextran nanoparticles as a promising platform for advanced vaccines. This platform offers improved ability to stimulate an immune response and controlled delivery of the antigen. These findings have significant implications for global health efforts focused on preventing Typhoid fever.